Nasdaq4d
Piper says Myriad appears to be trading down on GeneSight coverage change
Piper Sandler thinks Myriad Genetics (MYGN), which has seen its shares fall nearly 22% on Friday morning, is trading down on a coverage decision on GeneSight by UnitedHealth (UNH), which will take ...
How are Americans feeling before Election Day?
Election season is in full swing, but as anyone can tell you, campaigns begin to enter their full speed much earlier in the ...
EurekAlert!1y
The GeneSight Test (IMAGE)
With a simple cheek swab, the GeneSight test generates a report that gives healthcare providers insight into how a patient may metabolize or respond to certain psychiatric medications.
Nasdaq4d
UnitedHealth update ‘not the end’ for Myriad’s GeneSight, says Raymond James
UnitedHealth (UNH) on Friday disclosed that it would stop covering multi-panel pharmacogenetic tests, including Myriad’s (MYGN) GeneSight, effective January 1, 2025, in a number of plans ...
Psychology Today2y
Blue Water Psychiatry
Your brain health is our business. We offer GeneSight® Psychotropic testing for those who may not be responding to multiple medication trials. We offer treatment for depression, anxiety ...
Myriad Genetics comments on UnitedHealthcare’s updated policy
Myriad Genetics (MYGN) was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to ...